KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design.

Robert L Ferris, Hisham Mehanna, Jonathan D Schoenfeld, Makoto Tahara, Sue S Yom, Robert Haddad, André König, Pauline Witzler, Marcis Bajars, Christophe Le Tourneau

Future Oncol 20(12) 739-748

PMID38197296
PMCID-
DOI10.2217/fon-2023-0774
发表日期2024-01-10
摘要

摘要

There is a significant unmet need and lack of treatment options for patients with resected, high-risk, cisplatin-ineligible locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Xevinapant, a first-in-class, potent, oral, small-molecule IAP inhibitor, is thought to restore cancer cell sensitivity to chemotherapy and radiotherapy in clinical and preclinical studies. We describe the design of XRay Vision (NCT05386550), an international, randomized, double-blind, phase III study. Approximately 700 patients with resected, high-risk, cisplatin-ineligible LA SCCHN will be randomized 1:1 to receive 6 cycles of xevinapant or placebo, in combination with radiotherapy for the first 3 cycles. The primary end point is disease-free survival, and secondary end points include overall survival, health-related quality of life, and safety.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。